Novartis AG Profit Margin 2010-2023 | NVS

Current and historical gross margin, operating margin and net profit margin for Novartis AG (NVS) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Novartis AG net profit margin as of June 30, 2023 is 14.76%.
Novartis AG Annual Profit Margins
Novartis AG Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $218.128B $50.545B
Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $545.807B 73.71
Johnson & Johnson (JNJ) United States $421.553B 15.63
Novo Nordisk (NVO) Denmark $419.696B 44.33
Merck (MRK) United States $272.428B 38.21
AbbVie (ABBV) United States $270.917B 12.15
AstraZeneca (AZN) United Kingdom $206.679B 18.68
Pfizer (PFE) United States $191.906B 7.05
Sanofi (SNY) $138.534B 12.39
Innoviva (INVA) United States $0.813B 9.25